David Malcom Rodman Sells 14,058 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) insider David Malcom Rodman sold 14,058 shares of Mineralys Therapeutics stock in a transaction dated Monday, April 13th. The stock was sold at an average price of $26.54, for a total transaction of $373,099.32. Following the transaction, the insider owned 76,140 shares of the company’s stock, valued at approximately $2,020,755.60. The trade was a 15.59% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

David Malcom Rodman also recently made the following trade(s):

• On Wednesday, April 15th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $27.66, for a total transaction of $175,585.68.
• On Thursday, April 9th, David Malcom Rodman sold 2,170 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $27.38, for a total transaction of $59,414.60.
• On Thursday, March 12th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $27.37, for a total value of $173,744.76.
• On Friday, March 13th, David Malcom Rodman sold 14,058 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $26.26, for a total value of $369,163.08.
• On Monday, March 9th, David Malcom Rodman sold 2,171 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $26.84, for a total value of $58,269.64.
• On Tuesday, February 17th, David Malcom Rodman sold 417 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $27.59, for a total value of $11,505.03.
• On Thursday, February 12th, David Malcom Rodman sold 6,349 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $28.99, for a total value of $184,057.51.
• On Friday, February 13th, David Malcom Rodman sold 14,055 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $27.44, for a total value of $385,669.20.
• On Monday, February 9th, David Malcom Rodman sold 2,171 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $30.21, for a total value of $65,585.91.
• On Tuesday, January 20th, David Malcom Rodman sold 416 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $32.10, for a total value of $13,353.60.

Mineralys Therapeutics Stock Performance

Mineralys Therapeutics stock traded up $3.10 during midday trading on Wednesday, reaching $30.42. 3,180,291 shares of the company were exchanged, compared to its average volume of 1,310,737. The company has a market capitalization of $2.51 billion, a price-to-earnings ratio of -12.84 and a beta of 0.69. The firm’s 50-day simple moving average is $27.26 and its 200-day simple moving average is $34.36. Mineralys Therapeutics, Inc. has a 1 year low of $12.59 and a 1 year high of $47.65.

Mineralys Therapeutics (NASDAQ:MLYS) last released its earnings results on Thursday, March 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.17. On average, analysts forecast that Mineralys Therapeutics, Inc. will post -4.23 EPS for the current fiscal year.

Institutional Investors Weigh In On Mineralys Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. AQR Capital Management LLC acquired a new stake in Mineralys Therapeutics in the 1st quarter valued at $550,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Mineralys Therapeutics by 4.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,085 shares of the company’s stock worth $271,000 after purchasing an additional 702 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Mineralys Therapeutics by 166.6% in the first quarter. Goldman Sachs Group Inc. now owns 298,395 shares of the company’s stock worth $4,739,000 after buying an additional 186,480 shares during the period. Woodline Partners LP purchased a new stake in shares of Mineralys Therapeutics in the first quarter worth about $757,000. Finally, Creative Planning acquired a new stake in shares of Mineralys Therapeutics in the second quarter valued at about $336,000. 84.46% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on MLYS shares. Wall Street Zen raised shares of Mineralys Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, March 15th. Jefferies Financial Group restated a “hold” rating and set a $30.00 target price on shares of Mineralys Therapeutics in a research report on Friday, March 13th. Stifel Nicolaus lifted their target price on shares of Mineralys Therapeutics from $45.00 to $52.00 and gave the stock a “buy” rating in a research note on Friday, December 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Mineralys Therapeutics in a report on Thursday, January 22nd. Finally, Bank of America increased their price target on Mineralys Therapeutics from $46.00 to $51.00 and gave the stock a “buy” rating in a research note on Friday, March 13th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $49.14.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.